Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Gurnell

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Hormone Research in Paediatrics|July 11, 2022
Early Postnatal Use of Glibenclamide in Permanent Neonatal Diabetes Secondary to Antenatally Diagnosed KJCN11 MutationSandra Walton-Betancourth, Jennifer Ashford, Kathy Beardsall, et al.
The Journal of Clinical Endocrinology and Metabolism|November 15, 2007
Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trialEleanor M Gurnell, Penelope J Hunt, Suzanne E Curran, et al.
Pituitary|June 6, 2022
Modern imaging in Cushing's diseaseW A Bashari, D Gillett, J MacFarlane, et al.
The Journal of Clinical Endocrinology and Metabolism|May 18, 2006
Elevated plasma adiponectin in humans with genetically defective insulin receptorsR K Semple, M A Soos, J Luan, et al.
The Journal of Biological Chemistry|February 22, 2000
A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesisM Gurnell, J M Wentworth, M Agostini, et al.
Nature|January 6, 2000
Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertensionI Barroso, M Gurnell, V E Crowley, et al.
Endocrinology|December 1, 1999
Three novel mutations at serine 314 in the thyroid hormone beta receptor differentially impair ligand binding in the syndrome of resistance to thyroid hormoneM Gurnell, O Rajanayagam, M Agostini, et al.
Seminars in Oncology|September 29, 2018
Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumabR T Casey, O Giger, I Seetho, et al.
QJM : Monthly Journal of the Association of Physicians|January 11, 2018
Oncogenic osteomalaciaA K Annamalai, A J Gill, A Shinto, et al.
QJM : Monthly Journal of the Association of Physicians|August 3, 2012
Hypopituitarism, pulmonary infiltration and a spontaneously resolving occipital massA K Annamalai, A S Powlson, N Kandasamy, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Hormone Research in Paediatrics|July 11, 2022
Early Postnatal Use of Glibenclamide in Permanent Neonatal Diabetes Secondary to Antenatally Diagnosed KJCN11 MutationSandra Walton-Betancourth, Jennifer Ashford, Kathy Beardsall, et al.
The Journal of Clinical Endocrinology and Metabolism|November 15, 2007
Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trialEleanor M Gurnell, Penelope J Hunt, Suzanne E Curran, et al.
Pituitary|June 6, 2022
Modern imaging in Cushing's diseaseW A Bashari, D Gillett, J MacFarlane, et al.
The Journal of Clinical Endocrinology and Metabolism|May 18, 2006
Elevated plasma adiponectin in humans with genetically defective insulin receptorsR K Semple, M A Soos, J Luan, et al.
The Journal of Biological Chemistry|February 22, 2000
A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesisM Gurnell, J M Wentworth, M Agostini, et al.
Nature|January 6, 2000
Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertensionI Barroso, M Gurnell, V E Crowley, et al.
Endocrinology|December 1, 1999
Three novel mutations at serine 314 in the thyroid hormone beta receptor differentially impair ligand binding in the syndrome of resistance to thyroid hormoneM Gurnell, O Rajanayagam, M Agostini, et al.
Seminars in Oncology|September 29, 2018
Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumabR T Casey, O Giger, I Seetho, et al.
QJM : Monthly Journal of the Association of Physicians|January 11, 2018
Oncogenic osteomalaciaA K Annamalai, A J Gill, A Shinto, et al.
QJM : Monthly Journal of the Association of Physicians|August 3, 2012
Hypopituitarism, pulmonary infiltration and a spontaneously resolving occipital massA K Annamalai, A S Powlson, N Kandasamy, et al.
Pageof 5